课题基金 / 基金详情

The mechanism of CML leukemia progenitor cells eradication uncovered by Sipa1 deficiency

The mechanism of CML leukemia progenitor cells eradication uncovered by Sipa1 deficiency
Sipa1缺陷揭示的CML白血病祖细胞根除机制
批准号:
18F18406
负责人:
湊 長博
金额:
$1.47万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for JSPS Fellows
财政年份:
2018
资助国家:
日本
项目状态:
已结题
起止时间:
2018-10-12 至 2021-03-31

项目摘要

项目成果

湊 長博的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In this study, we have confirmed that Sipa1-deficient (Sipa1-/-) mice showed increased resistance to different epithelial cancer cells such as MC38 intestinal and IPmN pancreatic cancers in addition to chronic myelogenous leukemia (CML) stem cells. We performed single cell RNA sequencing (scRNA-seq) analysis of tumor stromal cells to investigate the involvement of the tissue stromal response in the anti-tumor mechanism. The analysis results revealed that tumor tissue mesenchymal stromal cells (MSCs) consisted of 3 major subtypes, FA, FB, and FC, with distinct gene expression profiles. We identified these 3 different tumor MSC subtypes quantitatively by FACS analysis using specific cell surface markers. With the analysis, we found that MSCs in the tumor tissue of Sipa1-/- hosts showed preferential increase in FC and FB subtypes, which have both immunoregulatory and extracellular matrix (ECM)-regulatory functions, respectively, as compared to those of wild type (WT) hosts. Furthermore, we also found that the tumor MSCs of Sipa1-/- hosts exhibited enhanced expression of T-cell chemokine gene compared to those of WT hosts. In order to verify their topological relation to tumor cells and infiltrated T cells in WT and Sipa1-/- hosts, tissue immuno-staining analysis was also performed to identify the three MSCs subtypes in situ in various tumor tissues.All of our results have suggested that host Sipa1-deficiency causes altered pattern of MSC development and their gene expression profile in tumor tissues, leading to the enhanced local T-cell immunity against tumor cells.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
第78回日本癌学会学術総会
第 78 届日本癌症学会年会
DOI: --
发表时间: 2019
期刊:
影响因子: --
作者: []
通讯作者:
he 17th International Congress of Immunology (IUIS 2019)
第十七届国际免疫学大会(IUIS 2019)
DOI: --
发表时间: 2019
期刊:
影响因子: --
作者: []
通讯作者:
Sipa1 deficiency unleashes a potent host anti-cancer immune mechanism
Sipa1缺陷释放出有效的宿主抗癌免疫机制
DOI: --
发表时间: 2019
期刊:
影响因子: --
作者: [Yan Xu, Satoshi Ikeda, Kentaro Sumida, Ryusuke Yamamoto, Hiroki Tanaka, Nagahiro Minato]
通讯作者: Nagahiro Minato
Sipa1 which controls stromal activation and T-cell recruitment in cancer tissue may be a new checkpoint component for cancer immunity
Sipa1控制癌组织中的基质激活和T细胞募集,可能是癌症免疫的新检查点成分
DOI: --
发表时间: 2019
期刊:
影响因子: --
作者: [Yan Xu]
通讯作者: Yan Xu
生体防御と免疫病制御の統合的パラダイム
  • 批准号:
    18639002
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.18万
  • 财政年份:
    2006
  • 负责人:
    湊 長博
  • 依托单位:
低分子G蛋白質Rap1シグナルによる造血細胞の分化制御と白血病化機構の解明
  • 批准号:
    04F04652
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
  • 资助金额:
    $0.77万
  • 财政年份:
    2004
  • 负责人:
    湊 長博
  • 依托单位:
レパートリー形成の分子機構
  • 批准号:
    08282103
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas (A)
  • 资助金额:
    $109.25万
  • 财政年份:
    1999
  • 负责人:
    湊 長博
  • 依托单位:
MHC非拘束性T細胞の抗原レセプターと認識抗原の研究
  • 批准号:
    07257212
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
  • 资助金额:
    $2.56万
  • 财政年份:
    1995
  • 负责人:
    湊 長博
  • 依托单位:
国内基金
海外基金
基于苯二氮䓬并喹唑啉酮骨架的新型先导化合物协同hUC-MSCs增效抗肝缺血再灌注损伤的作用及机制研究
  • 批准号:
    2026JJ82473
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    李勇
  • 依托单位:
基于 hUC-MSCs外泌体miR-455-5p/TRIM33/Smad轴调控子宫内膜自噬修复宫腔粘连的机制研究
  • 批准号:
    JCZRLH202600971
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
MSCs调节血小板GPVI介导中性粒细胞募集、迁移与NETosis治疗ARDS的机制研究